|
Derivation of class II force fields: V. Quantum force field for amides, peptides, and related compounds
|
journal
|
March 1998 |
|
Derivation of class II force fields. VI. Carbohydrate compounds and anomeric effects
|
journal
|
May 1998 |
|
Derivation of Class II Force Fields. III. Characterization of a Quantum Force Field for Alkanes
|
journal
|
January 1994 |
|
Derivation of class II force fields. I. Methodology and quantum force field for the alkyl functional group and alkane molecules
|
journal
|
February 1994 |
|
Synthetic Macrocycles in Small-Molecule Drug Discovery
|
book
|
September 2013 |
|
On the size of the active site in proteases. I. Papain
|
journal
|
April 1967 |
|
A new synthesis of α-arylglycines from aryl boronic acids
|
journal
|
December 1997 |
|
A convenient procedure for the synthesis of 1-tetralone derivatives using a Suzuki coupling-Friedel-Crafts acylation sequence
|
journal
|
January 1998 |
|
An efficient synthesis of 2-(3-(4-amidinophenylcarbamoyl)naphthalen-2-yl)-5-((2,2-methylpropyl)carbamoyl)benzoic acid: a factor VIIa inhibitor discovered by the Ono Pharmaceutical Company
|
journal
|
August 2000 |
|
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix
|
journal
|
June 2003 |
|
Optimization of a screening lead for factor VIIa/TF
|
journal
|
September 2001 |
|
Design, synthesis, and structure–activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors
|
journal
|
April 2003 |
|
Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex
|
journal
|
July 2003 |
|
Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library☆
|
journal
|
March 2005 |
|
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
|
journal
|
August 2006 |
|
Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand
|
journal
|
December 2006 |
|
Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands
|
journal
|
January 2007 |
|
Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores
|
journal
|
June 2009 |
|
Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition
|
journal
|
July 2004 |
|
Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors
|
journal
|
February 2005 |
|
Structure-based design and synthesis of pyrazinones containing novel P1 ‘side pocket’ moieties as inhibitors of TF/VIIa
|
journal
|
June 2005 |
|
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
|
journal
|
December 2005 |
|
The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex
|
journal
|
November 2005 |
|
The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex—Part 2
|
journal
|
February 2006 |
|
Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model
|
journal
|
April 2006 |
|
Discovery of novel heterocyclic factor VIIa inhibitors
|
journal
|
April 2006 |
|
Factor VIIa inhibitors: Improved pharmacokinetic parameters
|
journal
|
April 2006 |
|
Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability
|
journal
|
April 2006 |
|
Novel 5-azaindole factor VIIa inhibitors
|
journal
|
June 2006 |
|
Efforts toward oral bioavailability in factor VIIa inhibitors
|
journal
|
July 2006 |
|
Potent 4-amino-5-azaindole factor VIIa inhibitors
|
journal
|
September 2006 |
|
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
|
journal
|
November 2006 |
|
Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF–FVIIa inhibitors
|
journal
|
March 2013 |
|
Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor
|
journal
|
April 2013 |
|
Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
|
journal
|
September 2013 |
|
Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold
|
journal
|
September 2013 |
|
Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors
|
journal
|
May 2015 |
|
Tissue factor–fVIIa inhibition: update on an unfinished quest for a novel oral antithrombotic
|
journal
|
September 2014 |
|
Recombinant Nematode Anticoagulant Protein c2 in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
|
journal
|
June 2007 |
|
Administration of a small molecule tissue factor/Factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time
|
journal
|
January 2003 |
|
The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor
|
journal
|
January 2006 |
|
Derivation of Class II Force Fields. 2. Derivation and Characterization of a Class II Force Field, CFF93, for the Alkyl Functional Group and Alkane Molecules
|
journal
|
March 1994 |
|
Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa
|
journal
|
April 1994 |
|
Relationship of Stereochemical and Skeletal Diversity of Small Molecules to Cellular Measurement Space
|
journal
|
November 2004 |
|
Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants
|
journal
|
October 2003 |
|
Design, Parallel Synthesis, and Crystal Structures of Pyrazinone Antithrombotics as Selective Inhibitors of the Tissue Factor VIIa Complex
|
journal
|
September 2003 |
|
Design, Synthesis, and Crystal Structure of Selective 2-Pyridone Tissue Factor VIIa Inhibitors
|
journal
|
September 2003 |
|
Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery
|
journal
|
April 2011 |
|
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
|
journal
|
September 2013 |
|
Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening
|
journal
|
February 2015 |
|
Macrocyclic Amino Carboxylates as Selective MMP-8 Inhibitors
|
journal
|
May 1998 |
|
Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters
|
journal
|
November 1995 |
|
Chiral synthesis via organoboranes. 9. Crystalline chelates from borinic and boronic esters. A simple procedure for upgrading borinates and boronates to materials approaching 100% optical purity
|
journal
|
November 1986 |
|
Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors
|
journal
|
December 2013 |
|
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
|
journal
|
March 1996 |
|
The exploration of macrocycles for drug discovery — an underexploited structural class
|
journal
|
July 2008 |
|
A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo
|
journal
|
March 2005 |
|
Features and development of Coot
|
journal
|
March 2010 |
|
Pharmacological Interruption of Acute Thrombus Formation with Minimal Hemorrhagic Complications by a Small Molecule Tissue Factor/Factor VIIa Inhibitor: Comparison to Factor Xa and Thrombin Inhibition in a Nonhuman Primate Thrombosis Model
|
journal
|
June 2003 |
|
Crystallographic R Factor Refinement by Molecular Dynamics
|
journal
|
January 1987 |
|
Assessment of Bleeding Propensity in Non-Human Primates by Combination of Selective Tissue Factor/VIIa Inhibition and Aspirin Compared to Warfarin and Aspirin Treatment
|
journal
|
January 2004 |
|
Antithrombotic and Antilesion Benefits without Hemorrhagic Risks by Inhibiting Tissue Factor Pathway
|
journal
|
January 1996 |
|
BMS-593214, an active site-directed factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies
|
journal
|
January 2010 |
|
Antithrombotic Effects of Recombinant Human, Active Site–Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis
|
journal
|
January 1998 |
|
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis
|
journal
|
August 2007 |
|
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement
|
journal
|
July 2001 |
|
Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients
|
journal
|
July 2014 |
|
The Design and Synthesis of Noncovalent Factor Xa Inhibitors
|
journal
|
June 2001 |